Finland· FI-REL-REL36707

Rasilamlo

A aliskiren and amlodipine product containing aliskiren hemifumarate + amlodipine besylate, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 2 of our 19 countries.

ATC C09XA53

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedRasilamloATCC09XA53REGISTER NO.FI-REL-REL36707PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Aliskiren and amlodipine is registered in 2 of 19 countries.

Countries holding a registration under ATC C09XA53 (aliskiren and amlodipine), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 2 of them publish a price we can compare per daily dose

Aliskiren and amlodipine · ATC C09XA53

2 / 19 countries

  • Belgiumprice
  • Finlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Aliskiren hemifumarate + Amlodipine besylate
Manufacturer
Novartis Europharm Limited
Country
Finland (FI)
ATC code
C09XA53
ATC class
Aliskiren and amlodipine
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

54 interactions on record for aliskiren and amlodipine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Aliskiren and amlodipine · interactions on record

54 records

54 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b05bed12-d052-43ff-91b2-1b47a4c7556f
GET /v1/drugs/b05bed12-d052-43ff-91b2-1b47a4c7556f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "tabletti, kalvopäällysteinen",
  "route": null,
  "ddd_unit": null,
  "strength": "150 mg / 10 mg",
  "atc_label": "aliskireeni ja amlodipiini",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/1/11/686/015-028",
  "fimea_rel_id": "REL36707",
  "authorised_at": "2011-04-14"
}

See everything about aliskiren and amlodipine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.